Krystal Biotech, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| KRYS | BHVN | 688382.SS | IDYA | BBIO | KOD | |
|---|---|---|---|---|---|---|
| Market cap | 9.21B | 2.30B | 8.38B | 3.12B | 15.17B | 6.19B |
| P/E (TTM) | 42.2 | — | — | — | — | — |
| Forward P/E | 34.0 | -8.2 | -43.8 | -7.9 | -225.0 | -28.7 |
| Price/book | 6.4 | -23.4 | 6.6 | 2.9 | -5.9 | 101.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +55.44% | +78.66% | −48.70% | +8.41% | +24.17% | +482.90% |
| Today | +1.90% | −2.37% | +4.33% | +3.29% | +5.21% | −0.38% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All KRYS news ›Krystal Biotech (KRYS) and Its Peers Financial Survey
Posted by Kim Johansen on Nov 4th, 2026 Krystal Biotech (NASDAQ:KRYS – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Krystal Biotech…
Krystal Biotech Sinks 11% Despite Q3 Beat as Eye Trial Enrollment “Progressed Slower Than Initially Anticipated”
freedomz and utah778 from Getty Images via Canva Krystal Biotech (KRYS) just beat estimates, and the stock sank 11% anyway. Vyjuvek, its gene therapy for a rare blistering skin disease, brought in $127.3 million in the third quarter, up…
Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results
$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch VYJUVEK pricing negotiations in Germany and Italy completed KB113 clinical data demonstrate regression in more than 80% of assessed basal cell carcinoma lesions in…
TD Cowen maintains Krystal Biotech at Buy, lowers price target to $380 from $403
TradingView TD Cowen maintains Krystal Biotech at Buy, lowers price target to $380 from $403 TD Cowen maintained Krystal Biotech at Buy and lowered its price target to $380 from $403, a 5.7% decrease. The price target
Krystal Biotech falls as data for pipeline programs pushed to 2027
Krystal Biotech stock fell after delaying pipeline data to 2027 despite a Q3 earnings beat. Read more here. - Despite releasing Q3 financial results that beat on both lines, Krystal Biotech (KRYS) is down ~13% in Monday morning trading…
Krystal Biotech GAAP EPS of $2.05 beats by $0.28, revenue of $1.1B beats by $973.46M
Krystal Biotech Q3 earnings crushed estimates with strong EPS and revenue growth. - Krystal Biotech press release (KRYS): Q3 GAAP EPS of $2.05 beats by $0.28. - Revenue of $1.1B (+1024.7% Y/Y) beats by $973.46M. - Cash, cash equivalents…
Krystal Integrated Services posts negative first-half cash flow
Welcome to Multibagg AI Log in to access personalized features Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and…
Krystal Integrated Services to Announce Q2 FY27 Results Today
Welcome to Multibagg AI Log in to access personalized features Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and…
Krystal Biotech Analyst Says Stock Weakness 'Overblown'
Krystal Biotech Inc. KRYS stock is trading lower on Monday after the company provided a third-quarter update. The biotech company reported earnings of $2.05 per share, beating the consensus of $1.77. Sales reached $127.341 million, beating…
Krystal Biotech’s Vyjuvek sales jump 30% but net income slips (NASDAQ: KRYS)
Posted by Danessa Lincoln on Nov 2nd, 2026 Krystal Biotech, Inc. (NASDAQ: KRYS) said Vyjuvek net product revenue rose 30% to $127.3 million in the third quarter of 2026. That compares with $97.8 million a year earlier. The company said…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- seekingalpha.com8
- themarketsdaily.com3
- tradingview.com3
- investors.com2
- multibagg.ai2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 25 articles, not a forecast.